Education
About Us
Working with TipRanks
Follow Us
PAVmed Inc (PAVM)
NASDAQ:PAVM
PAVM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.57 - $2.66
Previous CloseN/A
Volume127.06K
Average Volume (3M)199.62K
Market Cap
$12.89M
Enterprise Value$36.48M
Total Cash (Recent Filing)$19.64M
Total Debt (Recent Filing)$48.73M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 19, 2025EPS Estimate
-0.13Last Dividend Ex-Date
Jan 11, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding16,787,172
10 Day Avg. Volume174,770
30 Day Avg. Volume199,617
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.22
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.19
Enterprise Value/Ebitda3.09
Forecast
1Y Price Target
$4.00Price Target Upside433.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
PAVmed News
PremiumCompany Announcements
Pavmed’s Strategic Growth and Financial Challenges
PremiumCompany Announcements
PAVmed Reports Strong Q4 Results and Strategic Progress
---
Bulls Say, Bears Say
Bulls Say
Commercialization And GrowthLucid’s high growth and ramp up in commercialization will be a major catalyst for PAVmed’s stock.
Market PotentialPAVmed’s market potential in digital health and medtech, especially in cancer care, presents high rewards for the risks.
ValuationPAVmed is considered significantly undervalued based on a sum-of-the-parts analysis, indicating potential upside.
Bears Say
Price TargetMaintaining a BUY rating, but lowering the 12-month price target to $21 represents significant upside from the current share price.
Revenue EstimatesRevenue estimates for 2025 and 2026 have been lowered due to a slower expected ramp in patients.
---
Ownership Overview
5.78%
Insiders
1.45% Mutual Funds
6.71% Other Institutional Investors
91.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $0.57 and its highest was $2.66 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $12.89M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is May 19, 2025 which is in 50 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on Mar 24, 2025. The company reported $0.132 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.242.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc pays a Notavailable dividend of $0.551 which represents an annual dividend yield of N/A. See more information on PAVmed Inc dividends here
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.13.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 16,787,172 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of $0.132 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of PAVmed Inc?
Among the largest hedge funds holding PAVmed Inc’s share is Cruiser Capital Advisors, Llc. It holds PAVmed Inc’s shares valued at 0.
---
Company Description
PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
---
PAVM Company Deck
---
PAVM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a company stabilizing its operations with strategic transformations and strong growth in its subsidiaries. Lucid Diagnostics shows promising revenue growth and insurance breakthroughs, while Veris Health secures financing and strategic partnerships. However, challenges with debt restructuring and dependency on further financing present ongoing concerns.Read More>---
PAVM Stock 12 Month Forecast
Average Price Target
$4.00
▲(433.33% Upside)
Technical Analysis
Best Analysts Covering PAVM
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-51.15%
reiterated a buy rating 4 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -51.15% per trade.
---